This study included Iourty chronic renal failure patients aged 37 -83 years (mean 51.3±7) on thrice weekly I-IDx for 4 -144 month (KtN> 1.2).
serurn Ca and iCa were significantly lower in group I after CA compared to values after CC (p<o.n I). Similar results in Ca levels were observed in group II (P<0.05).
In group II only serurn I' was significantly lower after C A compared to its values after CC (1'<0.05).
There was no signilïcant difference in AI', U, Cr, ALT, AST, TI' and Alb before, and at the end of each month of CA and CC treatment (1'>0.05 in ail). We excluded 12.Yk of cases due to CA intolerance while non of cases had similar intolerance to Cc. 2) CA can be safely increased without the risk of hypercalcemia. 3) Active Vitamin D and high dialysate Ca can be used to suppress parathyroid activity more safely with CA than with Cc. -l ) Tolerability to CC is superior.
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Introduction l lypcrphosphatemia plays a major role in renal osteodystrophy
19J. 
Aim of work
This prospective double blind crossover study was designed to compare equivalent amounts of calcium acetate and calcium carbonate (in terms of elemental calcium)
in the control of hyperphosphatemia in chronic renal failure patients maintained on regular hemodialysis.
Materials and methods
Fourty hemodialysis patients were studied. Their age ranged between 37 and 83 years (mean ±SD=5 1.3±7). They were 31 male and 9 female on thrice weekly hemodialysis for 4 -144 months using the same type of dialyzer membrane, namely cuprophane, and the time of dialysis session was individualized to keep Kt / Y> 1. 
Results
Five patients (12.5%) did not tolerate calcium acetate because of nausea, vomiting and upper GIT upset.
They were excluded as non-compliant patients. Three other patients died during the course of study. The rest of the patients (32, 16 in each group) showed good tolerance for both calcium acetate and calcium carbonate. The results are summarized in tables 1,2 and Figures 1-3. PI: Probability values in comparing the studied parameter at onset of study to its value after I month or calcium acetate. P2: Probability values in comparing the studied parameter at onset of study to its value after I month of calcium carbonate. P3: Probability values in comparing the studied parameter after I month of calcium acetate to its value after I month or calcium carbonate. 1992. This could be explained by:
I. Duration of treatment was too short to affect alkaline phosphatase level as it is not a sensitive parameter in assessing calcium-phosphorus homeostasis in the short run. 2. The decrease in serum total calcium and ionized calcium may neutralize the suppressing effect of decreased serum phosphorus on parathyroid gland.
3.
Patients included in this study had initially normal serurn alkaline phosphatase ancl thus the effect of either compound on this level will not be appreciable.
It can be concluded that calcium acetate is a goocl alternative to calcium carbonate as phosphate-binder with the following advantages: It is slightly more effective and is not associated with hypercalcemia.
It even decreases the serum calcium level allowing any increase in the close. A dialysate containing high calcium concentration (6-7 mg%) can be used without fear of hypercalcemia.
The co-administration of active vitamin D will be possible allowing more effective control of serum calcium and PTII. 
